Progress on norovirus vaccine research: public health considerations and future directions
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
i

Superseded

This Document Has Been Replaced By:

i

Retired

This Document Has Been Retired

i

Up-to-date Information

This is the latest update:

Progress on norovirus vaccine research: public health considerations and future directions
  • Published Date:

    August 27 2018

  • Source:
    Expert Rev Vaccines. 17(9):773-784
  • Language:
    English
Filetype[PDF-330.42 KB]


Details:
  • Alternative Title:
    Expert Rev Vaccines
  • Personal Author:
  • Description:
    Introduction: Noroviruses are the leading cause of foodborne illness worldwide, account for approximately one-fifth of acute gastroenteritis (AGE) cases globally, and cause a substantial economic burden. Candidate norovirus vaccines are in development, but there is currently no licensed vaccine. Areas covered: Noroviruses cause approximately 684 million cases and 212,000 deaths per year across all age groups, though burden estimates vary by study and region. Challenges to vaccine research include substantial and rapidly evolving genetic diversity, short-term and homotypic immunity to infection, and the absence of a single, well-established correlate of protection. Nonetheless, several norovirus vaccine candidates are currently in development, utilizing virus-like particles (VLPs), P particles, and recombinant adenoviruses. Of these, a bivalent GI.1/GII.4 VLP-based intramuscular vaccine (Phase IIb) and GI.1 oral vaccine (Phase I) are in clinical trials. Expert Commentary: A norovirus vaccine should target high-risk populations, including the young and the elderly, and protect them against the most common circulating norovirus strains. A norovirus vaccine would be a powerful tool in the prevention and control of norovirus while lessening the burden of AGE worldwide. However, more robust burden and cost estimates are needed to justify investments in and guide norovirus vaccine development.
  • Subject:
  • Pubmed ID:
    30092671
  • Pubmed Central ID:
    PMC6410563
  • Document Type:
    Journal Article
  • Funding:
    CC999999/Intramural CDC HHS/United States
  • Collection(s):
    CDC Public Access
  • Main Document Checksum:
  • File Type:
No Related Documents.

You May Also Like:

  1. Filetype[PDF - 4.17 MB]
    Personal Author:
    Lopman, Benjamin A.
    Corporate Authors:
    Centers for Disease Control and Prevention (U.S.). Bill & Melinda Gates Foundation.. CDC Foundation..
    Published Date:
    August 2015
    Description:
    The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention, or the US Department of Health and Human Services.This work was funded in p...
    File Type:
    Filetype[PDF - 4.17 MB]
  2. Filetype[PDF - 35.75 KB]
    Personal Author:
    Kissoon, Niranjan; Uyeki, Timothy M.;
    Published Date:
    Feb 2016
    Source:
    JAMA Pediatr. 170(2):107-108
    File Type:
    Filetype[PDF - 35.75 KB]
  3. Filetype[PDF - 109.96 KB]
    Personal Author:
    Aliabadi, Negar; Lopman, Ben A; Parashar, Umesh D; Hall, Aron J;
    Published Date:
    July 29 2015
    Source:
    Expert Rev Vaccines. 14(9):1241-1253
    Description:
    Human norovirus infection causes significant medical and financial costs in the USA and abroad. Some populations, including young children, the elderly, and the immunocompromised, are at heightened risk of infection with this virus and subsequent com...
    File Type:
    Filetype[PDF - 109.96 KB]
  4. Filetype[PDF - 2.69 MB]
    Personal Author:
    Mushkin, Selma J.; Collings, Francis d'A.;
    Published Date:
    Sep 1959
    Source:
    Public Health Rep. 74(9):795-809
    File Type:
    Filetype[PDF - 2.69 MB]
  5. Filetype[PDF - 1.74 MB]
    Personal Author:
    Chan, Martin C.W.; Hu, Yunwen; Chen, Haili; Podkolzin, Alexander T.; Zaytseva, Ekaterina V.; Komano, Jun; Sakon, Naomi; Poovorawan, Yong; Vongpunsawad, Sompong; Thanusuwannasak, Thanundorn; Hewitt, Joanne; Croucher, Dawn; Collins, Nikail; Vinjé, Jan; Pang, Xiaoli L.; Lee, Bonita E.; de Graaf, Miranda; van Beek, Janko; Vennema, Harry; Koopmans, Marion P.G.; Niendorf, Sandra; Poljsak-Prijatelj, Mateja; Steyer, Andrej; White, Peter A.; Lun, Jennifer H.; Mans, Janet; Hung, Tin-Nok; Kwok, Kirsty; Cheung, Kelton; Lee, Nelson; Chan, Paul K.S.;
    Published Date:
    Aug 2017
    Source:
    Emerg Infect Dis. 23(8):1350-1354.
    Description:
    Analysis of complete capsid sequences of the emerging norovirus GII.17 Kawasaki 308 from 13 countries demonstrated that they originated from a single haplotype since the initial emergence in China in late 2014. Global spread of a sublineage SL2 was i...
    File Type:
    Filetype[PDF - 1.74 MB]